ArticleObesity surgery2026
The Weight of the Matter: Preoperative Metabolic Dysfunction-Associated Steatotic Liver Disease and its Limited Impact on Bariatric Outcomes.
Article in Obesity surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMetabolically-dysfunction-associated steatotic liver disease (MASLD) is a prevalent comorbidity of obesity, with metabolic bariatric surgery (MBS) suggested as the only definitive treatment. Concerns have been raised about altered weight loss patterns in patients with MASLD undergoing MBS; therefore, we aimed to evaluate the influence of MASLD on postoperative weight loss patterns after Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy (SG).
methodData from 347 patients who underwent MBS between 2020 and 2024 were retrospectively reviewed. Patients were followed at 1, 6, and 12 months postoperatively. Weight, body mass index (BMI), excess weight loss (EWL), and total weight loss (TWL) were compared both by the presence of MASLD and by the different ultrasound-determined grades of MASLD.
resultAfter 12 months postoperatively, weight and BMI were lower in the no MASLD groups than in the MASLD group (74.61 vs. 77.04 for weight and 28.49 vs. 29.21 for BMI in the RYGB group, and 71.03 vs. 74.92 for weight and 27.41 vs. 29.05 for BMI in the SG group). However, after adjusting for age, sex, history of diabetes, baseline BMI, and baseline weight, as well as the alimentary and biliopancreatic limbs in RYGB, multivariate analysis of repeated measures ANOVA revealed that the overall pattern of the MASLD group was statistically similar to that of the no MASLD group.
conclusionPreoperative MASLD does not appear to influence weight loss outcomes after RYGB or SG significantly. Larger prospective studies are required to clarify the predictive value of MASLD on postoperative weight loss patterns after MBS.
Indexed as
Identifiers
41968217What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.